Company profile
Sintx Technologies, Inc.
NASDAQ: SINT · Healthcare · Medical - Devices
#874 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
35DFH 22DQ 54GM 29SS 50
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$1.0M
Rev growth YoY (TTM)
-37.9%
Net income (FY)
-$10.4M
Employees
32
as of 2026-08-23
Market cap
$9.9M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.0M$1.0M2025
Net income-$10.4M-$10.4M2025
Operating income-$10.7M-$10.7M2025
Total assets$9.5M$9.5M2025
Liabilities$6.6M$6.6M2025
Equity$2.9M$2.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product72%
Grant and Contract28%
By geography
Not disclosed.
The read
What is Sintx Technologies, Inc.’s revenue?
Sintx Technologies, Inc. booked $1.0M in FY2025 revenue, contracting 65% year over year — slower than 85% of Healthcare companies we track, at a -1018.1% net margin.
Peers · Healthcare
Orgenesis Inc.——Marijuana Company of America, Inc.——Dare Bioscience, Inc.36DEhouse Global, Inc.——60 Degrees Pharmaceuticals, Inc.34DShattuck Labs, Inc.49DNeighbors
Salt Lake →Key facts
CEOEric K. Olson
SectorHealthcare
IndustryMedical - Devices
HeadquartersSalt Lake City, UT
ExchangeNASDAQ: SINT
Employees32
IPO date2014-02-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.